1. Anti-infection NF-κB Apoptosis
  2. Influenza Virus Fungal NF-κB Apoptosis
  3. Hyperoside

Hyperoside  (Synonyms: Quercetin 3-O-galactoside; Quercetin 3-O-β-D-galactopyranoside)

Cat. No.: HY-N0452 Purity: 99.71%
Handling Instructions Technical Support

Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis.

For research use only. We do not sell to patients.

CAS No. : 482-36-0

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 21 publication(s) in Google Scholar

Other Forms of Hyperoside:

Top Publications Citing Use of Products

    Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Jan 27:123417.  [Abstract]

    Hyperoside (HPS) (10 μM; 8 d) significantly inhibited the lipid accumulation induced by MDI in SVF and 3 T3-L1 cells.

    Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Jan 27:123417.  [Abstract]

    Hyperoside (HPS) (10 μM; 8 d) effectively restored the expressions of C/EBPα and FABP4 in SVF and 3 T3-L1 cells to levels comparable to the control.

    Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Jan 27:123417.  [Abstract]

    Low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment markedly decreased the number of cystic follicles in polycystic ovary syndrome (PCOS) mice.

    Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Jan 27:123417.  [Abstract]

    High-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment effectively reversed changes of FSH, LH, progesterone, and testosterone in polycystic ovary syndrome (PCOS) mice, while low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) improved all hormone levels except FSH.

    Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Jan 27:123417.  [Abstract]

    Both low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatments led to a reduction in fasting serum glucose levels and improved insulin sensitivity in polycystic ovary syndrome (PCOS) mice.

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis[1][2].

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    > 10 μg/mL
    Compound: Compound 7
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25862199]
    C2C12 EC50
    60.5 μM
    Compound: 11
    Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting
    Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting
    [PMID: 22738356]
    HeLa IC50
    > 10 μg/mL
    Compound: Compound 7
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 25862199]
    MDCK CC50
    > 431 μM
    Compound: Hyperoside
    Cytotoxicity against MDCK cells
    Cytotoxicity against MDCK cells
    [PMID: 25096296]
    RAW264.7 IC50
    48.8 μM
    Compound: 16
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis
    [PMID: 24679441]
    RAW264.7 IC50
    > 50 μM
    Compound: 16
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
    [PMID: 24679441]
    SGC-7901 IC50
    > 10 μg/mL
    Compound: Compound 7
    Cytotoxicity against human SGC7901 cells by MTT assay
    Cytotoxicity against human SGC7901 cells by MTT assay
    [PMID: 25862199]
    In Vitro

    Hyperoside (12.5-100 μM; 6-24 h) inhibits MCF-7 and 4T1 cell growth[2].
    Hyperoside (25-100 μM; 24 h) induces apoptosis of breast cancer cells[2].
    Hyperoside inhibits the activation of the NF-κB signaling pathway via the attenuation of intracellular ROS generation[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[2]

    Cell Line: MCF-7 and 4T1 cells
    Concentration: 12.5, 25, 50, 75, or 100 µM
    Incubation Time: 6, 12, or 24 h
    Result: Inhibited cell growth in a time- and concentration-dependent manner.

    Apoptosis Analysis[2]

    Cell Line: MCF-7 and 4T1 cells
    Concentration: 25, 50 and 100 µM
    Incubation Time: 24 h
    Result: Increased the expressions of Bax, cleaved caspase-3 and cleaved PARP, and decreased Bcl-2 in mRNA and protein levels.
    In Vivo

    Hyperoside (intraperitoneal injection; 50 mg/kg; every two day for 18 days) treatment inhibits breast tumor growth in vivo[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Balb/c mice injected with 4T1 cells[2]
    Dosage: 50 mg/kg
    Administration: Intraperitoneal injection; 50 mg/kg; every two day for 18 days
    Result: Reduced the average tumor volume compared to the control group.
    Decreased Bcl-2 and increased bax and cleaved caspase-3.
    Molecular Weight

    464.38

    Formula

    C21H20O12

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 125 mg/mL (269.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1534 mL 10.7670 mL 21.5341 mL
    5 mM 0.4307 mL 2.1534 mL 4.3068 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (21.53 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.71%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1534 mL 10.7670 mL 21.5341 mL 53.8352 mL
    5 mM 0.4307 mL 2.1534 mL 4.3068 mL 10.7670 mL
    10 mM 0.2153 mL 1.0767 mL 2.1534 mL 5.3835 mL
    15 mM 0.1436 mL 0.7178 mL 1.4356 mL 3.5890 mL
    20 mM 0.1077 mL 0.5384 mL 1.0767 mL 2.6918 mL
    25 mM 0.0861 mL 0.4307 mL 0.8614 mL 2.1534 mL
    30 mM 0.0718 mL 0.3589 mL 0.7178 mL 1.7945 mL
    40 mM 0.0538 mL 0.2692 mL 0.5384 mL 1.3459 mL
    50 mM 0.0431 mL 0.2153 mL 0.4307 mL 1.0767 mL
    60 mM 0.0359 mL 0.1795 mL 0.3589 mL 0.8973 mL
    80 mM 0.0269 mL 0.1346 mL 0.2692 mL 0.6729 mL
    100 mM 0.0215 mL 0.1077 mL 0.2153 mL 0.5384 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Hyperoside
    Cat. No.:
    HY-N0452
    Quantity:
    MCE Japan Authorized Agent: